28207495|t|Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk
28207495|a|To highlight recently published studies addressing lipid changes with disease-modifying antirheumatic drug use and outline implications on cardiovascular outcomes in rheumatoid arthritis (RA). Growing evidence suggests lower lipid levels are present in patients with active RA vs. general population, and significant modifications of lipid profile with inflammation suppression. Increase in lipid levels in patients with RA on synthetic and biological disease-modifying antirheumatic drugs may be accompanied by antiatherogenic changes in lipid composition and function. The impact of lipid changes on cardiovascular outcomes in RA is a subject of active research. The role of lipids in cardiovascular risk in RA may be overpowered by the benefits of inflammation suppression with antirheumatic medication use. Recommendations on lipid management in RA are evolving but uncertainty exists regarding frequency of lipid testing and goals of treatment. Knowledge about quantitative and qualitative lipid changes in RA is expanding. The relative role of lipids in cardiovascular risk in the context of systemic inflammation and antirheumatic therapy remains uncertain, delaying development of effective strategies for cardiovascular risk management in RA. Studies are underway to address these knowledge gaps and may be expected to inform cardiovascular risk management in RA and the general population.
28207495	0	6	Lipids	T109	C0023779
28207495	11	16	lipid	T109	C0023779
28207495	17	24	changes	T169	C0392747
28207495	30	39	synthetic	T121	C4054347
28207495	44	97	biologic disease-modifying antirheumatic drug therapy	T061	C1303166
28207495	101	121	rheumatoid arthritis	T047	C0003873
28207495	140	159	cardiovascular risk	T047	C0850624
28207495	192	199	studies	T062	C2603343
28207495	211	216	lipid	T109	C0023779
28207495	217	224	changes	T169	C0392747
28207495	230	266	disease-modifying antirheumatic drug	T121	C0242708
28207495	299	313	cardiovascular	T029	C3887460
28207495	314	322	outcomes	T169	C1274040
28207495	326	346	rheumatoid arthritis	T047	C0003873
28207495	348	350	RA	T047	C0003873
28207495	361	369	evidence	T078	C3887511
28207495	370	378	suggests	T078	C1705535
28207495	385	397	lipid levels	T034	C0428460
28207495	402	409	present	T033	C0150312
28207495	413	421	patients	T101	C0030705
28207495	427	433	active	T169	C0205177
28207495	434	436	RA	T047	C0003873
28207495	441	459	general population	T098	C0683971
28207495	465	476	significant	T078	C0750502
28207495	477	490	modifications	T033	C3840684
28207495	494	499	lipid	T109	C0023779
28207495	494	507	lipid profile	T059	C0850354
28207495	513	525	inflammation	T046	C0021368
28207495	526	537	suppression	T040	C0301625
28207495	539	547	Increase	T169	C0442805
28207495	551	563	lipid levels	T034	C0428460
28207495	567	575	patients	T101	C0030705
28207495	581	583	RA	T047	C0003873
28207495	587	596	synthetic	T121	C4054347
28207495	601	611	biological	T080	C0205460
28207495	612	649	disease-modifying antirheumatic drugs	T121	C0242708
28207495	672	687	antiatherogenic	T121	C0684286
28207495	688	695	changes	T169	C0392747
28207495	699	704	lipid	T109	C0023779
28207495	705	716	composition	T201	C0486616
28207495	721	729	function	T169	C0542341
28207495	735	741	impact	T080	C4049986
28207495	745	750	lipid	T109	C0023779
28207495	751	758	changes	T169	C0392747
28207495	762	776	cardiovascular	T029	C3887460
28207495	777	785	outcomes	T169	C1274040
28207495	789	791	RA	T047	C0003873
28207495	808	823	active research	T062	C0035168
28207495	837	843	lipids	T109	C0023779
28207495	847	866	cardiovascular risk	T047	C0850624
28207495	870	872	RA	T047	C0003873
28207495	899	907	benefits	T081	C0814225
28207495	911	923	inflammation	T046	C0021368
28207495	924	935	suppression	T040	C0301625
28207495	941	965	antirheumatic medication	T121	C0003191
28207495	971	1006	Recommendations on lipid management	T058	C1272213
28207495	990	995	lipid	T109	C0023779
28207495	1010	1012	RA	T047	C0003873
28207495	1017	1025	evolving	T169	C0332253
28207495	1059	1068	frequency	T079	C0376249
28207495	1072	1077	lipid	T109	C0023779
28207495	1072	1085	lipid testing	T059	C0850354
28207495	1090	1095	goals	T170	C0679840
28207495	1099	1108	treatment	T169	C1522326
28207495	1110	1119	Knowledge	T170	C0376554
28207495	1126	1138	quantitative	T081	C0392762
28207495	1143	1154	qualitative	T080	C0205556
28207495	1155	1160	lipid	T109	C0023779
28207495	1161	1168	changes	T169	C0392747
28207495	1172	1174	RA	T047	C0003873
28207495	1178	1187	expanding	T082	C0205229
28207495	1193	1201	relative	T080	C0205345
28207495	1210	1216	lipids	T109	C0023779
28207495	1220	1239	cardiovascular risk	T047	C0850624
28207495	1247	1254	context	T078	C0449255
28207495	1258	1279	systemic inflammation	T047	C3646020
28207495	1284	1305	antirheumatic therapy	T061	C1303166
28207495	1334	1345	development	T169	C1527148
28207495	1349	1369	effective strategies	UnknownType	C0679723
28207495	1374	1393	cardiovascular risk	T047	C0850624
28207495	1394	1404	management	T058	C0376636
28207495	1408	1410	RA	T047	C0003873
28207495	1412	1419	Studies	T062	C2603343
28207495	1450	1459	knowledge	T170	C0376554
28207495	1495	1514	cardiovascular risk	T047	C0850624
28207495	1515	1525	management	T058	C0376636
28207495	1529	1531	RA	T047	C0003873
28207495	1540	1558	general population	T098	C0683971